ABBV ▲ +1.2% - AbbVie Inc.
$ABBV - AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
22-OCT-2026 09:01 AM ET
Share this post
More filings for $ABBV
ABBV ▼ -0.6% - AbbVie Inc.Oct 21, 2026ABBV ▲ +0.4% - AbbVie Inc.Oct 20, 2026ABBV ▲ +1.3% - AbbVie Inc.Oct 19, 2026ABBV ▲ +1.3% - AbbVie Inc.Oct 17, 2026ABBV ▼ -2.4% - AbbVie Inc.Oct 13, 2026ABBV ▲ +1.5% - AbbVie Inc.Oct 11, 2026
View full $ABBV filing history →💬 Comments
Loading comments…
Leave a comment